Everads-Therapy


Invest with us
Hagai Drori
hdrori@everads-therapy.com
Our Team
  • Hagai Drori COO
    More than 12 years of managerial experience in medical device development. Prior to Everads-Therapy, Hagay served as a Product Line Manager at DALI Medical Devices, CEO at NewVert Ltd, Project leader at Expanding Orthopedics Inc., Impliant Ltd, and Elcam Medical Ltd.
    B.Sc. in Mechanical Engineering from Tel Aviv University, and M.E. in System Engineering from the Technion-Israel Institute of Technology.
  • Dr. Ygal Rotenstreich MD ,Medical Director
    Dr. (MD) Ygal Rotenstreich is the Director of the Electrophysiology Unit at Tel Hashomer Medical Center, Israel and the Director of the Retinal Research Laboratory at the Goldschleger Eye Institute, Tel Hashomer. 
    He is also a lecturer at Tel-Aviv Univ., Sackler School of Medicine.  Dr. Rotenstreich led numerous research activities between them leading the project of developing treatments and novel diagnostic tools for retinal degeneration financed within the last 15 years as well as the Network of Excellence in Neuroscience grant (TEVA). 
    Dr. Rotenstreich is leading both basic and clinical research on retina disorders and have published more than 50 per-reviewed articles.
  • Dr. Ifat Sher Ph.D, Research Manager
  • David Daily, DALI Medical Devices, R&D
    David Daily Established DALI Medical Devices in 2003, DALI develops and customizes injectable drug delivery products that meet specific end-user and high-volume manufacturing requirements. DALI brings injectable drug delivery devices from concept to commercialization for pharmaceutical and medical device companies as well as patients, physicians, and hospitals.
    Since 1991, David acquired a broad range of experience in various R&D positions in the Israeli Defense Forces. From 1998 to 2003, while employed at Elan Medical Technologies Israel, a subsidiary of Elan Corporation (Ireland), David led the development of a variety of drug delivery devices, including disposable auto injectors and micro-infusion systems.
    ęDavid received an MSc degree in biomedical engineering and a BSc degree in mechanical engineering from the Technion-Israel Institute of Technology in Haifa. He also received an Executive MBA and graduated with honors from the Hebrew University of Jerusalem. 
  • Product Development

  • Everads-Therapy is developing a revolutionary drug and cell delivery system for delivery into the back of the eye.

    Posterior segment diseases of the eye are sight threatening and hard to treat due to their chronic and relapsing nature. 

    Everads technology targets the delivery of therapies into the extravascular matrix of the choroid .

    Feasibility studies in rabbit and pig models showed promising results.